Go to the list of all blogs
Anna G's Avatar
published in Blogs
May 21, 2023
Analyzing the Downturn: Unveiling the Story Behind Hims & Hers Health's (HIMS) -12.69% Monthly Descent

Analyzing the Downturn: Unveiling the Story Behind Hims & Hers Health's (HIMS) -12.69% Monthly Descent

Unlocking the Power of Artificial Intelligence to Make Trading Decisions with Tickeron's AI Robots.

In the competitive realm of healthcare and personal care, Hims & Hers Health (HIMS) faced a challenging month, witnessing a significant downturn of -12.69% and closing at $9.77 per share. This blog post aims to unravel the story behind Hims & Hers Health's notable setback, shedding light on the broader trends within the Household/Personal Care Industry. Join us as we dive into the analysis, examining the factors that contributed to the company's descent and exploring the market landscape that influenced its performance.

Understanding the Household/Personal Care Industry: To gain insights into Hims & Hers Health's performance, it is essential to understand the dynamics of the Household/Personal Care Industry. Our analysis of 95 stocks in this sector reveals that 47.37% exhibited an Uptrend, while 52.63% experienced a Downtrend. This industry overview sets the stage for comprehending the specific challenges and opportunities faced by Hims & Hers Health.

Factors Impacting Hims & Hers Health's Descent: Multiple factors may have influenced Hims & Hers Health's -12.69% monthly decline. Market conditions, competitive pressures, regulatory changes, or internal operational factors could have played a role in the company's setback. By examining these factors in detail, we can gain valuable insights into the circumstances that impacted Hims & Hers Health's performance.

Navigating the Landscape of Household/Personal Care: As investors evaluate the impact of Hims & Hers Health's descent, it becomes crucial to navigate the Household/Personal Care Industry with a discerning eye. Understanding the current market outlook, identifying potential opportunities, and assessing the risks associated with the sector are vital considerations for informed decision-making. This blog post provides valuable insights and strategies to help investors navigate the ever-evolving landscape of the Household/Personal Care Industry amidst Hims & Hers Health's downturn.

Hims & Hers Health's -12.69% monthly descent serves as a reminder of the volatility and challenges inherent in the Household/Personal Care Industry. By analyzing the broader market trends and uncovering the factors that influenced Hims & Hers Health's performance, investors can gain a comprehensive understanding of the landscape. In an industry that continues to evolve rapidly, staying informed, adapting to market conditions, and identifying potential opportunities while managing risks are crucial for investors seeking success in the Household/Personal Care sector.

Related Ticker: HIMS

HIMS in -7.77% downward trend, falling for three consecutive days on August 06, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where HIMS declined for three days, in of 287 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day moving average for HIMS crossed bearishly below the 50-day moving average on July 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

The Aroon Indicator for HIMS entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HIMS's RSI Oscillator exited the oversold zone, of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 61 cases where HIMS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on August 07, 2026. You may want to consider a long position or call options on HIMS as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for HIMS just turned positive on August 07, 2026. Looking at past instances where HIMS's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

HIMS moved above its 50-day moving average on August 07, 2026 date and that indicates a change from a downward trend to an upward trend.

The 50-day moving average for HIMS moved above the 200-day moving average on July 30, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where HIMS advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .

HIMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. HIMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.474) is normal, around the industry mean (40.267). P/E Ratio (57.137) is within average values for comparable stocks, (102.305). Projected Growth (PEG Ratio) (2.155) is also within normal values, averaging (2.202). HIMS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.033). P/S Ratio (3.401) is also within normal values, averaging (114.263).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.05B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -0%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 25%. ZYBT experienced the highest price growth at 35%, while SXTC experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -7%. For the same stocks of the Industry, the average monthly volume growth was 7% and the average quarterly volume growth was -17%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 64
Price Growth Rating: 57
SMR Rating: 88
Profit Risk Rating: 83
Seasonality Score: -3 (-100 ... +100)
View a ticker or compare two or three
HIMS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a company, which is involved in real estate investment trusts

Industry PharmaceuticalsGeneric

Profile
Details
Industry
N/A
Address
2269 Chestnut Street
Phone
+1 415 851-0195
Employees
658
Web
https://www.forhims.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Analyzing the Downturn: Unveiling the Story Behind Hims & Hers Health's (HIMS) -12.69% Monthly Descent